Under-Valued Dividend Growers: 8 Stocks Averaging A 10.2x P/E

I screen U.S.-listed dividend growth stocks with 2–6% yields, strong revenue growth, and disciplined payout ratios, targeting undervalued opportunities. The final 8-stock portfolio spans Energy, Financials, Materials, Consumer Discretionary, Healthcare, and Industrials, with a weighted yield of 3.79% and 5-year dividend growth of 20.92% with a factor weight. Portfolio construction emphasizes forward P/E below 20, price to cash flow between 5x–10x, and mid/large caps with proven top-line expansion.

Seeking Alpha • 21 hours ago

Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union

NVO's denecimig wins a positive European opinion for hemophilia A, with flexible dosing and a potential 2026 launch.

Zacks Investment Research • Sep 18, 2026

Congressman Ditches Magnificent Seven Stocks for Consumer Staples: Here's What He Bought

A member of Congress recently disclosed numerous stock trades, with some new names bought and some of the Magnificent Seven stocks sold. Here's a look at the trades and the Congress member's trading history.

Benzinga • Sep 18, 2026

40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"

Raul Shah (@Raul_DSF) is very bullish on the future of GLP-1s due to accelerating demand trends generating a "mania" effect in the market. He points to the superiority Eli Lilly (LLY) has demonstrated through earnings and weighs if Novo (NVO) has a chance to catch up.

Patients are suing GLP-1 drugmakers over the risk of sudden vision loss. The little-discussed potential risk of popular diabetes and weight-loss drugs is on warning labels outside of the U.S.

Michelle Fennell was sitting at her desk when her right eye started feeling heavy. Suddenly, it was blurry and her peripheral vision waned. It felt like she was looking through a fishbowl, she could see straight ahead but not to her right or down.

WSJ • Sep 19, 2026

Novo, Orbis sign up to $1.4 billion deal to develop oral drugs

Orbis Medicines said on Thursday it had signed a drug discovery and licensing deal with Novo Nordisk worth ​up to $1.4 billion to develop oral therapies for cardiometabolic diseases that are ‌traditionally treated with injectable drugs.

Reuters • Sep 17, 2026

Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery

NVO is expanding its AI strategy with Anthropic to tackle drug discovery challenges, boost R&D productivity and develop new medicines faster.

Zacks Investment Research • Sep 17, 2026

EMA Committee Endorses Novo Nordisk's Hemophilia A Therapy

Novo Nordisk A/S (NYSE:NVO) stock is trading higher on Thursday after the Danish drug maker achieved major advances across its therapeutic pipeline after securing a key European regulatory recommendation for its hemophilia A treatment and launching a major cardiometabolic research partnership.

Benzinga • Sep 17, 2026

Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?

NVO's 5% drop in a week reflects intensifying GLP-1 competition and semaglutide risks, but its broad pipeline offers potential long-term growth.

Zacks Investment Research • Sep 17, 2026

Orbis Medicines Enters Multi-Target Drug Discovery Partnership with Novo Nordisk Worth up to USD 1.4 Billion

COPENHAGEN, Denmark--(BUSINESS WIRE)--Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a strategic collaboration and license agreement with Novo Nordisk to discover and develop next-generation oral macrocycle therapeutics for cardiometabolic diseases. The agreement enables the acceleration of the development of a new class of orally available medicines for high-value therapeutic targets. Under the terms of the agreement, Orbis Medicines is eligible to receive up to U.

Business Wire • Sep 17, 2026